These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 8889283)

  • 1. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline.
    Dingemanse J; Kneer J; Wallnöfer A; Kettler R; Zürcher G; Koulu M; Korn A
    Clin Neuropharmacol; 1996 Oct; 19(5):399-414. PubMed ID: 8889283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
    Koulu M; Scheinin M; Kaarttinen A; Kallio J; Pyykkö K; Vuorinen J; Zimmer RH
    Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
    Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM
    Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects.
    Berlin I; Zimmer R; Thiede HM; Payan C; Hergueta T; Robin L; Puech AJ
    Br J Clin Pharmacol; 1990 Dec; 30(6):805-16. PubMed ID: 1705137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression. A double blind, randomized study.
    Radat F; Berlin I; Spreux-Varoquaux O; Elatki S; Ferreri M; Puech AJ
    Psychopharmacology (Berl); 1996 Oct; 127(4):370-6. PubMed ID: 8923574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.
    Holford NH; Guentert TW; Dingemanse J; Banken L
    Br J Clin Pharmacol; 1994 May; 37(5):433-9. PubMed ID: 7519866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome".
    Dingemanse J; Wallnöfer A; Gieschke R; Guentert T; Amrein R
    Clin Pharmacol Ther; 1998 Apr; 63(4):403-13. PubMed ID: 9585794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of adverse interactions between concomitantly administered selegiline and citalopram.
    Laine K; Anttila M; Heinonen E; Helminen A; Huupponen R; Mäki-Ikola O; Reinikainen K; Scheinin M
    Clin Neuropharmacol; 1997 Oct; 20(5):419-33. PubMed ID: 9331518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.
    Van Haarst AD; Van Gerven JM; Cohen AF; De Smet M; Sterrett A; Birk KL; Fisher AL; De Puy ME; Goldberg MR; Musson DG
    Br J Clin Pharmacol; 1999 Aug; 48(2):190-6. PubMed ID: 10417495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites.
    Wiesel FA; Raaflaub J; Kettler R
    Eur J Clin Pharmacol; 1985; 28(1):89-95. PubMed ID: 3987791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
    Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
    J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline.
    Korn A; Wagner B; Moritz E; Dingemanse J
    Eur J Clin Pharmacol; 1996; 49(4):273-8. PubMed ID: 8857072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans.
    Heinonen EH; Anttila MI; Karnani HL; Nyman LM; Vuorinen JA; Pyykkö KA; Lammintausta RA
    J Clin Pharmacol; 1997 Jul; 37(7):602-9. PubMed ID: 9243353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations.
    Dingemanse J; Korn A; Pfefen JP; Güntert TW
    Psychopharmacology (Berl); 1992; 106 Suppl():S46-8. PubMed ID: 1347659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma.
    Hovevey-Sion D; Kopin IJ; Stull RW; Goldstein DS
    Neuropharmacology; 1989 Aug; 28(8):791-7. PubMed ID: 2506486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359.
    Kumagae Y; Matsui Y; Iwata N
    Jpn J Pharmacol; 1991 Jan; 55(1):121-8. PubMed ID: 1904113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
    Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
    Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
    Da Prada M; Kettler R; Keller HH; Burkard WP; Muggli-Maniglio D; Haefely WE
    J Pharmacol Exp Ther; 1989 Jan; 248(1):400-14. PubMed ID: 2783611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects.
    Dingemanse J; Wood N; Guentert T; Oie S; Ouwerkerk M; Amrein R
    Psychopharmacology (Berl); 1998 Nov; 140(2):164-72. PubMed ID: 9860107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
    Zimmer R
    Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.